Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Madrigal Pharmaceuticals (NASDAQ: MDGL) will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 1:30 PM PST. The presentation will be broadcast live and accessible via the company's Investor Relations Events and Presentations page, with a replay available after the event.
Positive
- None.
Negative
- None.
News Market Reaction – MDGL
In the Dec 16 session, MDGL declined 1.07%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 04 | Inducement awards | Neutral | -2.3% | Equity inducement grants to new non-executive employees under 2025 plan. |
| Nov 20 | Inducement awards | Neutral | +1.1% | RSU inducement awards to three new non-executive employees. |
| Nov 17 | Investor conferences | Neutral | +4.6% | Planned participation in three late-2025 healthcare investor conferences. |
| Nov 10 | Clinical data | Positive | +1.4% | Phase 3 data showing Rezdiffra improved imaging tests and biomarkers in MASH cirrhosis. |
| Nov 06 | Inducement awards | Neutral | +0.1% | Inducement RSU grants to 18 new non-executive employees. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent headlines mix clinical data, insider/employee equity actions, and conference participation, with generally moderate share price reactions around these events.
Over the last six weeks, Madrigal reported several equity inducement grants (Nov 6, Nov 20, Dec 4) and insider equity activity, alongside participation in multiple healthcare investor conferences announced on Nov 17. A notable clinical milestone came on Nov 10 with positive Phase 3 MAESTRO-NAFLD-1 data for Rezdiffra in compensated MASH cirrhosis. These developments occurred as the stock traded strongly above its 200-day moving average, and today’s J.P. Morgan conference notice continues that pattern of investor-focused communications.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CONSHOHOCKEN, Pa., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the J.P. Morgan Annual Healthcare Conference on Monday, January 12, 2026 at 1:30pm PST.
The presentation will be broadcast live and can be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event.
About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.
Investor Contact
Tina Ventura, IR@madrigalpharma.com
Media Contact
Christopher Frates, media@madrigalpharma.com
